PAX
Beyond's analysis on PAX
- — US customs clears STIIIZY's redesigned vape of Pax patent infringement, enabling its market release
Recent news mentioning PAX
- — Dilworth Paxson Expands New York Office with Insurance Team
- — Ken Paxton is right. Tax cuts will mean Social Security and Medicare cuts.
- — Sign In App Integrates with Paxton's Net2 to Unify Access Control and Real-Time On-Site Visibility
- — Grimaldi investe 1,5 miliardi in nove RoPax pronte per il net zero
- — Kazia Therapeutics Announces Sovargen Co. Doses First Patient in Phase 1b/2a Trial of Paxalisib for Rare Seizure Disorders
- — Always and Tampax Put Period Preparedness on the College Checklist
- — $250,000 Sitting in SPAXX Pays State Tax on Most of Its Interest While FDLXX Holders Pay Almost None
- — CPA Crossings Streamlines CPE Tracking and Compliance with CPAx Academy
- — ZONDISION Introduces Glasses-Free 3D Developer Ecosystem at PAX West 2026
- — Kazia Therapeutics Announces First Patient Dosed in PNOC035 Clinical Study Evaluating Paxalisib for Recurrent Pediatric AT/RT Brain Cancer
- — Kazia (KZIA) Raises Approximately $40M in Gross Proceeds and Expands Paxalisib. Is the Capital Base Stronger than the Clinical Evidence?
- — Kazia Therapeutics Reports Preclinical Data Showing Paxalisib Reprograms Immunotherapy-Resistant MSS/pMMR Colorectal Cancer and Enhances Response to Immunotherapy